Pharma BD Deal Intelligence
Gendaq's zinc-finger IP fueled two decades of licensing deals (Pfizer, Biogen, Genentech) but the platform ultimately liquidated in Sangamo's 2026 Chapter 11 bankruptcy for roughly what Sangamo paid for it in 2001.
Full analysis, sources & comparables →This acquisition reflects our belief that zinc finger DNA-binding protein transcription factors will be the dominant platform for targeted gene regulation,…
Eight patents on rules and libraries for constructing two-zinc-finger domains were previously owned by UK-based Gendaq Ltd., which was acquired by Sangamo in…
Motley Fool credited the Gendaq deal as 'critical' for Sangamo, but warned that competition from CRISPR and TALEN approaches makes ZFN-only investing 'risky'…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Below $250M but strategically notable: zinc-finger nuclease IP consolidation — foundational for Sangamo's ZFN gene-editing platform.
Gendaq's zinc-finger IP fueled two decades of licensing deals (Pfizer, Biogen, Genentech) but the platform ultimately liquidated in Sangamo's 2026 Chapter 11 bankruptcy for roughly what Sangamo paid for it in 2001.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sangamo BioSciences Inc. / Gendaq Limited (UK) (this deal) | 2001 | $40M | 36 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals